BioCardia (BCDA) Interest & Investment Income (2020 - 2021)
BioCardia's (BCDA) quarterly Interest & Investment Income came in at $1000.0 in Q4 2021, down 50.0% year-over-year from $2000.0 in Q4 2020, and down 50.0% quarter-over-quarter from $2000.0 in Q3 2021.
Powered by 
Analysis
BioCardia (BCDA) Interest & Investment Income (2020 - 2021) Analysis & Trends
BioCardia (BCDA) has reported Interest & Investment Income for 2 consecutive years, with $1000.0 the latest figure, recorded in Q4 2021.
- On a quarterly basis, Interest & Investment Income fell 50.0% year-over-year to $1000.0 in Q4 2021; TTM through Dec 2021 was $7000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $9000.0, down 57.14% from the prior year.
- Interest & Investment Income was $1000.0 for Q4 2021 at BioCardia, down from $2000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $2000.0 in Q2 2020 and troughed at $1000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 7.66 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -2.69 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 3.22 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 5.60 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 5.05 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 7.49 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 366,000.00 |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | - |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 1.95 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 2,000.00 |